Momelotinib dihydrochloride monohydrate is a salt and hydrate form of momelotinib, an orally bioavailable small molecule that inhibits Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant JAK2V617F, and activin A receptor type 1 (ACVR1/ALK2). It is used as an active pharmaceutical ingredient in the manufacture of pharmaceutical products, where its mechanism involves inhibition of the JAK-STAT signaling pathway and suppression of hepcidin formation.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1841094-17-4
Momelotinib
pharmaceutical raw material
Momelotinib dihydrochloride
pharmaceutical raw material
Olmutinib hydrochloride
pharmaceutical raw material
(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid--piperazine (2/1)
pharmaceutical raw material
Gefitinib
pharmaceutical raw material
Cofrogliptin
pharmaceutical raw material
4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoic acid
pharmaceutical intermediate
N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide;hydrate;dihydrochloride
RQKCPSIFARJBOR-UHFFFAOYSA-N
C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N.O.Cl.Cl